DDInter1102 DDInter1082
Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Lumateperone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Lumateperone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metformin
Lumateperone {u} may lead to a major life threatening interaction when taken with {v} Apalutamide
Lumateperone {u} may lead to a major life threatening interaction when taken with {v} Prednisone
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Metformin
Lumateperone may lead to a major life threatening interaction when taken with Apalutamide
Lumateperone may lead to a major life threatening interaction when taken with Prednisone